• 1
    Hauman CH,Thompson IO,Theunissen F,Wolfaardt P. Oral carriage of Candida in healthy and HIV-seropositive persons. Oral Surg Oral Med Oral Pathol. 1993; 76: 570572.
  • 2
    Bodey GP. Candidiasis in cancer patients. Am J Med. 1984; 77: 1319.
  • 3
    Mooney MA,Thomas I,Sirois D. Oral candidiasis. Int J Dermatol. 1995; 34: 759765.
  • 4
    Epstein JB,Polsky B. Oropharyngeal candidiasis: a review of its clinical spectrum and current therapies. Clin Ther. 1998; 20: 4057.
  • 5
    Peterson DE. Oral candidiasis. Clin Geriatr Med. 1992; 8: 513527.
  • 6
    Clarkson JE,Worthington HV,Eden OB. Interventions for treating oral candidiasis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2004;(1): CD001972.
  • 7
    Sonis ST,Elting LS,Keefe D, et al.; Mucositis Study Section of the Multinational Association for Supportive Care in Cancer, International Society for Oral Oncology. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004; 100(9 suppl ): 19952025.
  • 8
    Redding SW,Zellars RC,Kirkpatrick WR, et al. Epidemiology of oropharyngeal Candida colonization and infection in patients receiving radiation for head and neck cancer. J Clin Microbiol. 1999; 37: 38963900.
  • 9
    Ramirez-Amador V,Silverman SJr,Mayer P,Tyler M,Quivey J. Candida colonization and oral candidiasis in patients undergoing oral and pharyngeal radiation therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997; 84: 149153.
  • 10
    Epstein JB,Freilich MM,Le Nhu D. Risk factors for oropharyngeal candidiasis in patients who receive radiation therapy for malignant conditions of the head and neck. Oral Surg Oral Med Oral Pathol. 1993; 76: 169174.
  • 11
    Leung WK,Dassanayake RS,Yau JY,Jin LJ,Yam WC,Samaranayake LP. Oral colonization, phenotypic, and genotypic profiles of Candida species in irradiated, dentate, xerostomic nasopharyngeal carcinoma survivors. J Clin Microbiol. 2000; 38: 22192226.
  • 12
    Makkonen TA,Minn H,Jekunen A,Vilja P,Tuominen J,Joensuu H. Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study. Int J Radiat Oncol Biol Phys. 2000; 46: 525534.
  • 13
    Nicolatou-Galitis O,Dardoufas K,Markoulatos P, et al. Oral pseudomembranous candidiasis, herpes simplex virus-1 infection, and oral mucositis in head and neck cancer patients receiving radiotherapy and granulocyte-macrophage colony-stimulating factor (GM-CSF) mouthwash. J Oral Pathol Med. 2001; 30: 471480.
  • 14
    Pappas PG,Rex JH,Sobel JD, et al. Guidelines for the treatment of candidiasis. Clin Infect Dis. 2004; 38: 161189.
  • 15
    Munoz P,Fernandez-Turegano CP,Alcala L,Rodriguez-Creixems M,Pelaez T,Bouza E. Frequency and clinical significance of bloodstream infections caused by C. albicans strains with reduced susceptibility to fluconazole. Diagn Microbiol Infect Dis. 2002; 44: 163167.
  • 16
    Waltimo TM,Orstavik D,Meurman JH,Samaranayake LP,Haapasalo MP. In vitro susceptibility of Candida albicans isolates from apical and marginal periodontitis to common antifungal agents. Oral Microbiol Immunol. 2000; 15: 245248.
  • 17
    Kuriyama T,Williams DW,Bagg J,Coulter WA,Ready D,Lewis MA. In vitro susceptibility of oral Candida to 7 antifungal agents. Oral Microbiol Immunol. 2005; 20: 349353.
  • 18
    Ellepola ANB,Samaranayake LP. Antimycotic agents in oral candidosis: an overview: 2. Treatment of oral candidosis. Dent Update. 2000; 27: 165174.
  • 19
    Fothergill AW. Miconazole: a historical perspective. Expert Rev Anti Infect Ther. 2006; 4: 171175.
  • 20
    Cardot JM,Chaumont C,Dubray C,Costantini D,Aiache JM. Comparison of the pharmacokinetics of miconazole after administration via a bioadhesive slow release tablet and an oral to healthy male and female subjects. Br J Clin Pharmacol. 2004; 58: 345351.
  • 21
    Chaumont C,Cardot JM,Dubray C,Costantini D,Aiache JM. Safety, acceptability, and adhesion of a novel bioadhesive slow release tablet of miconazole in a phase I study. J Mycol Med. 2003; 13: 1318.
  • 22
    Silverman SJr. Oral cancer: complications of therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endol. 1999; 88: 122126.
  • 23
    Grotz K,Genitsariosis S,Vehling D,Al Nawas B. Candida colonization, mucositis and salivary function after head and neck radiotherapy. Support Care Cancer. 2003; 11: 717721.
  • 24
    Lefebvre JL,Domenge C. A comparative study of the efficacy and safety of fluconazole oral suspension and amphotericin B oral suspension in cancer patients with mucositis. Oral Oncol. 2002; 38: 337342.
  • 25
    Vazquez JA,Skiest DJ,Nieto L, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis. 2006; 42: 11791186.
  • 26
    Ruhnke M. Epidemiology of Candida albicans infections and role of non-Candida-albicans yeasts. Curr Drug Targets. 2006; 7: 495504.
  • 27
    Bassetti M,Righi E,Tumbarello M,Di Biagio A,Rosso R,Viscoli C. Candida infections in the intensive care unit: epidemiology, risk factors and therapeutic strategies. Expert Rev Anti Infect Ther. 2006; 4: 875885.